Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial | Cancer Biomarkers | JAMA Network Open | JAMA Network
Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial | Cancer Biomarkers | JAMA Network Open | JAMA Network: This secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial estimates the long-term risk of any prostate cancer and clinically significant prostate cancer associated with baseline prostate-specific antigen (PSA) levels among men aged 55 to 60 years.
Comments
Post a Comment